AI assistant
INOVIQ LTD — Capital/Financing Update 2019
Jun 17, 2019
65112_rns_2019-06-17_83d7cc2f-7397-401d-8e57-c86f8555fa02.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [155 x 46] intentionally omitted <==
18 JUNE 2019
PLACEMENT CLEANSING NOTICE
This notice is given by BARD1 Life Sciences Limited (ASX: BD1) ( Company ) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ( Act ).
The Company announced today a partially underwritten non-renounceable pro rata entitlement offer to shareholders with a registered address in Australia, New Zealand, Switzerland and Hong Kong of 1 fully paid ordinary share in the Company for every 10 fully paid ordinary shares in the Company held on the record date of 5.00pm (AWST) on 21 June 2019, at an issue price of $0.02 per share, to raise approximately $2.5 million (before costs).
The Company also announced today the completion of a placement, by which the Company has raised approximately $5 million (before costs) by the issue of 248,500,000 fully paid ordinary shares ( New Shares ) at an issue price of $0.02 per New Share.
The Company advises that:
-
the New Shares were issued without disclosure to investors under Part 6D.2 of the Act;
-
this notice is being given under paragraph 5(e) of section 708A of the Act;
-
as at the date of this notice, the Company has complied with:
-
(a) the provisions of Chapter 2M of the Act as they apply to the Company; and
-
(b) section 674 of the Act; and
-
-
as at the date of this notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Act which is required to be disclosed by the Company.
- ENDS -
FOR MORE INFORMATION PLEASE CONTACT:
Peter Gunzburg Dr Leearne Hinch Chairman CEO E [email protected] E [email protected] M +61 400 414 416
ABOUT BARD1 LIFE SCIENCES LTD
BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1’s vision is to detect cancer early and save lives. For more information on BARD1, see www.bard1.com.
BARD1 Life Sciences Limited (ABN 58 009 070 384) Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E [email protected] | W www.bard1.com